{"id":"arterolane-piperaquine","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Abdominal pain"}]},"_chembl":{"chemblId":"CHEMBL539666","moleculeType":"Small molecule","molecularWeight":"633.52"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Arterolane is a semi-synthetic artemisinin derivative that rapidly kills malaria parasites by generating reactive oxygen species and damaging parasite proteins. Piperaquine is a bisquinoline that accumulates in the parasite's food vacuole and inhibits heme detoxification, leading to parasite death. Together, they provide rapid parasite clearance and extended post-treatment suppression.","oneSentence":"Arterolane-piperaquine is a fixed-dose combination antimalarial that works by inhibiting parasite protein synthesis and disrupting the parasite's mitochondrial function.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:02:34.537Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Uncomplicated malaria caused by Plasmodium falciparum"},{"name":"Uncomplicated malaria caused by Plasmodium vivax"}]},"trialDetails":[{"nctId":"NCT03452475","phase":"PHASE3","title":"Comparison of Arterolane-piperaquine Versus Arterolane-piperaquine+Mefloquine Versus Artemether-lumefantrine in Kenyan Children","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2018-03-07","conditions":"Plasmodium Falciparum","enrollment":219},{"nctId":"NCT02461186","phase":"PHASE2, PHASE3","title":"Arterolane-PQP Versus DHA-PQP in Uncomplicated Falciparum Malaria in Eastern Myanmar","status":"WITHDRAWN","sponsor":"University of Oxford","startDate":"2015-06","conditions":"Uncomplicated Falciparum Malaria, Artemisinin-resistant","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Arterolane-piperaquine","genericName":"Arterolane-piperaquine","companyName":"University of Oxford","companyId":"university-of-oxford","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Arterolane-piperaquine is a fixed-dose combination antimalarial that works by inhibiting parasite protein synthesis and disrupting the parasite's mitochondrial function. Used for Uncomplicated malaria caused by Plasmodium falciparum, Uncomplicated malaria caused by Plasmodium vivax.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}